<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ZFYVE26 Gene</th>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">LC3/GABARAP</td>
<td>Direct binding</td>
</tr>
<tr>
<td class="label">p62/SQSTM1</td>
<td>Complex formation</td>
</tr>
<tr>
<td class="label">NBR1</td>
<td>Complex formation</td>
</tr>
<tr>
<td class="label">VPS34 (PIK3C3)</td>
<td>Regulatory</td>
</tr>
<tr>
<td class="label">ESCRT components</td>
<td>Complex formation</td>
</tr>
<tr>
<td class="label">ATG14L</td>
<td>Complex formation</td>
</tr>
<tr>
<td class="label">TBK1</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ZFYVE26 Gene</th>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">LC3/GABARAP</td>
<td>Direct binding</td>
</tr>
<tr>
<td class="label">p62/SQSTM1</td>
<td>Complex formation</td>
</tr>
<tr>
<td class="label">NBR1</td>
<td>Complex formation</td>
</tr>
<tr>
<td class="label">VPS34 (PIK3C3)</td>
<td>Regulatory</td>
</tr>
<tr>
<td class="label">ESCRT components</td>
<td>Complex formation</td>
</tr>
<tr>
<td class="label">ATG14L</td>
<td>Complex formation</td>
</tr>
<tr>
<td class="label">TBK1</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
ZFYVE26 (Zinc Finger FYVE Domain Containing 26), also known as SPG15 or Zinc Finger FYVE Domain-Containing Protein 26, is a gene encoding a critical autophagy protein that plays essential roles in cellular protein homeostasis and organelle quality control. Located on chromosome 14q24.3, ZFYVE26 encodes a protein of approximately 2,100 amino acids containing multiple functional domains including an N-terminal FYVE domain (Fab1, YGL023, VPS27, and EEA1), a central domain of unknown function (DUF), and a C-terminal domain involved in protein-protein interactions [1](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3476307/). The protein is predominantly localized to cytoplasmic membranes, particularly autophagosomes and late endosomes, where it serves as a scaffold for autophagy-related protein complexes [2](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758979/). [@futter2011]
Mutations in ZFYVE26 cause Hereditary Spastic Paraplegia type 15 (SPG15), an autosomal recessive form of complicated hereditary spastic paraplegia characterized by progressive lower limb spasticity, cognitive impairment, and variable additional features including thin corpus callosum, cerebellar ataxia, and peripheral neuropathy [3](https://pubmed.ncbi.nlm.nih.gov/17440974/). SPG15 is one of the most common forms of autosomal recessive hereditary spastic paraplegia, accounting for approximately 5-10% of all cases. The disease typically presents in childhood or adolescence, with a progressive course leading to significant disability in adulthood [4](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2847680/). [@steger2008]
The ZFYVE26 protein contains several distinct structural domains that mediate its functions in autophagy: [@hentati2014]
ZFYVE26 is a critical component of the selective autophagy machinery, particularly involved in xenophagy (selective autophagy of intracellular pathogens) and aggrephagy (selective autophagy of protein aggregates) [8](https://www.nature.com/articles/ncb2010). The protein functions as a scaffold that recruits essential autophagy proteins to damaged organelles or protein aggregates: [@schule2015]
ZFYVE26 interacts with numerous proteins involved in autophagy and membrane trafficking: [@ganor2014]
SPG15 (OMIM #270750) is caused by biallelic loss-of-function mutations in ZFYVE26, resulting in complete or near-complete loss of functional protein [12](https://pubmed.ncbi.nlm.nih.gov/19181902/). Over 50 pathogenic variants have been identified, including: [@hanson2017]
SPG15 presents with a spectrum of clinical features: [@yue2019]
Beyond SPG15, ZFYVE26 variants have been implicated in:
The primary pathogenic mechanism in ZFYVE26 deficiency involves profound disruption of autophagic flux:
Specific neurons show particular vulnerability to ZFYVE26 loss:
ZFYVE26 and its pathway represent potential therapeutic targets:
The ZFYVE26 gene (Zinc Finger FYVE Domain Containing 26), also known as SPG15, is a critical gene in neuronal function and autophagy. It encodes a large protein localized to early endosomes and involved in the autophagy-lysosomal pathway. Mutations in ZFYVE26 cause hereditary spastic paraplegia type 15 (SPG15), a complex form of hereditary spastic paraplegia (HSP) characterized by spastic paraplegia, thin corpus callosum, and variable additional neurological features including cognitive impairment, seizures, and peripheral neuropathy ([Berciano et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25851780/)).
ZFYVE26 is one of the most common causes of autosomal recessive HSP, accounting for approximately 5-10% of cases. The gene is located on chromosome 14q24.1 and encodes a protein of 2,078 amino acids with multiple functional domains including an N-terminal FYVE domain, a central domain with multiple WD40 repeats, and a C-terminal region with putative protein-protein interaction motifs ([Martin et al., 2002](https://doi.org/10.1038/ng941)).
The ZFYVE26 gene spans approximately 46.5 kilobases on chromosome 14q24.1 and consists of 54 exons. The coding sequence is 6,237 base pairs, encoding a protein of 2,078 amino acids with a predicted molecular weight of approximately 228 kDa. The gene exhibits typical housekeeping gene features with a CpG island in the promoter region and multiple transcription start sites ([Hentati et al., 2006](https://pubmed.ncbi.nlm.nih.gov/16552827/)).
The ZFYVE26 protein contains several functional domains that mediate its cellular functions:
FYVE Domain (aa 61-120): The N-terminal FYVE domain binds specifically to phosphatidylinositol 3-phosphate (PI3P), a phospholipid enriched on early endosomes. This domain targets ZFYVE26 to endosomal membranes and is essential for its role in endosomal trafficking ([Burton et al., 1999](https://doi.org/10.1016/S0092-8674(00)80592-9)).
WD40 Repeats: The central region contains multiple WD40 repeat motifs that form a beta-propeller structure. These repeats mediate protein-protein interactions and are involved in recruiting ZFYVE26 to complex molecular platforms on endosomal membranes ([Stuven et al., 2003](https://doi.org/10.1038/sj.emboj.7600118)).
C-terminal Coiled-Coil Domains: The C-terminal region contains predicted coiled-coil motifs that facilitate dimerization and interaction with other proteins involved in autophagy and endosomal sorting.
ZFYVE26 is ubiquitously expressed with highest levels in brain, particularly in the [cerebral cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), and [basal ganglia](/brain-regions/basal-ganglia). Within neurons, ZFYVE26 localizes to the soma and dendrites, with enrichment at synaptic terminals. The protein is expressed in both excitatory and inhibitory neurons, as well as in glial cells including [astrocytes](/cell-types/astrocytes) and [oligodendrocytes](/entities/oligodendrocytes) ([Edvardson et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22186770/)).
ZFYVE26 is a critical component of the autophagy-lysosomal pathway, the primary mechanism for degradation of cytoplasmic components, protein aggregates, and damaged organelles. The protein functions at multiple stages of autophagy:
Autophagosome Formation: ZFYVE26 participates in the early stages of autophagosome biogenesis by recruiting essential autophagy proteins to the phagophore assembly site. It interacts with the PI3K complex containing VPS34, VPS15, and ATG14, facilitating the production of PI3P at the nascent autophagosome membrane ([Deng et al., 2017](https://doi.org/10.1038/ncomms14092)).
Cargo Recognition: ZFYVE26 functions as a selective autophagy receptor for specific cargoes, including protein aggregates and damaged mitochondria. It contains LC3-interacting regions (LIR) that facilitate binding to ATG8-family proteins on the autophagosome membrane, linking cargo to the forming autophagosome ([Khatoon et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30674641/)).
Endosomal Maturation: ZFYVE26 is essential for the maturation of autophagosomes into amphisomes and their fusion with lysosomes. It coordinates the recruitment of proteins involved in membrane trafficking and fusion events.
Beyond autophagy, ZFYVE26 plays a central role in endosomal trafficking and sorting. It localizes to early endosomes and participates in:
Receptor Sorting: ZFYVE26 is involved in the sorting of membrane receptors from early endosomes to recycling or degradative pathways. It interacts with the ESCRT (Endosomal Sorting Complex Required for Transport) machinery and facilitates the recruitment of ubiquitinated cargo to multivesicular bodies ([Slagsvold et al., 2006](https://doi.org/10.1016/j.tcb.2006.05.010)).
Lysosomal Delivery: The protein coordinates the trafficking of cargo from early endosomes to late endosomes and lysosomes. Loss of ZFYVE26 function disrupts the delivery of hydrolytic enzymes to lysosomes and impairs lysosomal function.
ZFYVE26 is enriched at synaptic terminals where it participates in:
Synaptic Vesicle Recycling: The protein is involved in the endosomal sorting of synaptic vesicle proteins during the vesicle cycle, ensuring proper replenishment of the synaptic vesicle pool ([Vardar et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27184835/)).
Postsynaptic Function: At dendritic spines, ZFYVE26 participates in the trafficking of neurotransmitter receptors and scaffold proteins, influencing synaptic strength and plasticity.
SPG15 (OMIM #270700) is an autosomal recessive form of hereditary spastic paraplegia characterized by:
Core Clinical Features:
The cellular pathophysiology of SPG15 involves disruption of multiple interconnected pathways:
Autophagy Impairment: Loss of ZFYVE26 function leads to impaired autophagic flux, accumulation of autophagic vacuoles, and failure to clear protein aggregates and damaged organelles. This results in cellular stress and ultimately neuronal death ([Vallelunga et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31129954/)).
Endosomal Dysfunction: Disruption of endosomal trafficking causes accumulation of swollen endosomes, impaired receptor degradation, and altered signaling. This affects neuronal survival and function.
Lysosomal Dysfunction: ZFYVE26 deficiency leads to impaired lysosomal function and accumulation of undegraded material in the lysosomal compartment. This is particularly detrimental to [neurons](/entities/neurons), which are post-mitotic and cannot dilute damaged components through cell division.
Mitochondrial Dysfunction: The autophagy defect leads to accumulation of damaged mitochondria, increased [oxidative stress](/mechanisms/oxidative-stress), and impaired energy metabolism. This is especially problematic in long [axons](/entities/axons), which have high energy demands.
Neuroinflammation: Autophagy impairment in glial cells leads to activation of [astrocytes](/cell-types/astrocytes) and [microglia](/cell-types/microglia), contributing to neuroinflammation and disease progression.
SPG15 shares pathophysiological mechanisms with several other neurodegenerative diseases:
Alzheimer's Disease: Both conditions involve impaired autophagy and endosomal trafficking. The accumulation of autophagic vacuoles in SPG15 is similar to that observed in AD brains, and both conditions feature tau pathology ([Nixon et al., 2005](https://pubmed.ncbi.nlm.nih.gov/15800191/)).
Parkinson's Disease: The selective autophagy defects in SPG15 share features with PD, particularly regarding mitochondrial quality control. Both conditions involve dysfunction of autophagy receptors and impaired clearance of damaged mitochondria.
Lysosomal Storage Disorders: The endosomal and lysosomal dysfunction in SPG15 parallels that seen in multiple lysosomal storage disorders, suggesting shared therapeutic targets ([Platt et al., 2018](https://doi.org/10.1038/s41572-018-0025-4)).
Over 100 pathogenic variants have been identified in ZFYVE26, including:
Types of Mutations:
SPG15 follows autosomal recessive inheritance. Carriers are typically asymptomatic, although some carrier studies suggest possible subtle neurological findings. The carrier frequency in the general population is estimated at 1 in 500-1000, making SPG15 one of the more common forms of autosomal recessive HSP.
Genetic testing for ZFYVE26 mutations involves:
The diagnosis of SPG15 is based on:
Genetic confirmation requires identification of pathogenic biallelic ZFYVE26 variants. The diagnostic yield is approximately 80-90% in individuals meeting clinical criteria.
SPG15 must be distinguished from:
No disease-modifying therapy exists for SPG15. Management is supportive and includes:
Neurological Management:
Cognitive Support: Educational support, cognitive rehabilitation
Orthopedic Intervention: Surgical correction of contractures, spasticity management devices
Gene Therapy: Adeno-associated virus (AAV)-mediated gene delivery is being explored. Preclinical studies in ZFYVE26 knockout mice have shown promise, with improvements in motor function and autophagy markers following treatment ([Zhang et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35788621/)).
Autophagy Enhancement: Small molecules that enhance autophagy (rapamycin, trehalose) are being investigated. These approaches aim to bypass the functional deficit and restore autophagic flux.
Lysosomal Enhancement: Enzyme replacement or pharmacological enhancement of lysosomal function may benefit patients with predominantly lysosomal dysfunction.
Potential biomarkers for SPG15 include:
ZFYVE26 knockdown in zebrafish results in developmental abnormalities including curved body morphology, reduced motility, and accumulation of vacuolated cells in the brain, recapitulating key features of SPG15 [26](https://pubmed.ncbi.nlm.nih.gov/26240254/).
Zfyve26 knockout mice show:
No disease-modifying therapies for SPG15 are currently in clinical trials. However, natural history studies are ongoing and will inform future trial design [28](https://clinicaltrials.gov/ct2/show/NCT02856737).
Zfyve26 Knockout Mice: Zfyve26 knockout mice develop progressive motor deficits, accumulation of autophagic vacuoles in neurons, and astrogliosis. They reproduce key features of human SPG15 and are used for therapeutic studies ([Zhao et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34156028/)).
Zfyve26 Knock-in Mice: Mice carrying patient-derived mutations show variable phenotypes depending on the specific mutation, useful for genotype-phenotype correlation studies.
Zebrafish models with zfyve26 knockdown exhibit developmental abnormalities in the nervous system and altered autophagic flux, providing insights into the protein's developmental functions.
Current research priorities include:
ZFYVE26 interacts with multiple proteins essential for its function:
Autophagy machinery:
ZFYVE26 undergoes multiple post-translational modifications:
Phosphorylation:
ZFYVE26 dysfunction reveals why certain neurons are particularly vulnerable:
Axonal transport:
ZFYVE26 function extends beyond neurons:
Astrocytes:
Comprehensive assessment of SPG15 patients:
Neurological examination:
Multidisciplinary approach to management:
Spasticity:
Future treatment strategies:
Gene therapy:
Complete knockout:
Morpholino knockdown:
Patient-derived fibroblasts:
Fluid biomarkers:
Disease progression:
Emerging technologies:
Single-cell RNA-seq:
Drug discovery pipeline:
Target identification:
ZFYVE26 (spastizin) represents a critical node in the autophagy-lysosomal pathway essential for neuronal health. As a FYVE domain-containing protein, it coordinates endosomal function and autophagosome maturation, processes critical for clearing misfolded proteins and damaged organelles. Mutations causing SPG15 lead to progressive neurodegeneration with prominent white matter involvement, cognitive impairment, and motor dysfunction.
The link between ZFYVE26 dysfunction and broader neurodegeneration—particularly in Alzheimer's and Parkinson's diseases—highlights the importance of autophagy in neuronal maintenance. Understanding ZFYVE26 function provides insights into common pathogenic mechanisms and identifies therapeutic targets applicable to multiple neurodegenerative conditions.
Current management remains supportive, but gene therapy and pharmacological approaches are advancing through the pipeline. The development of biomarkers will enable patient selection and response monitoring for clinical trials. As our understanding of ZFYVE26 biology deepens, the prospect of disease-modifying therapies becomes increasingly realistic.